Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 2, 2001, Pages 68-79

  Tollemar, J ^a   Klingspor, L ^a   Ringden O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ERGOSTEROL; PLACEBO;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; CARDIOTOXICITY; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INFANT; LIVER TRANSPLANTATION; MALE; MYALGIA; MYCOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; PRIORITY JOURNAL; RECIPIENT; REVIEW; STEM CELL; UNIVERSITY HOSPITAL;

EID: 0035747145     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2001.tb00012.x     Document Type: Article

References (56)

1. Fungal Infection: Diagnosis and Management
2. Amphotericin B. toxicity. Combined clinical staff conference at the National Institutes of Health
3. A review of complications of amphotericin-B therapy: Recommendations for prevention and management
4. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: Glomerular thromboses and tubular injury
5. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes
6. Amphotericin B in liposomes: A novel therapy for histoplasmosis
7. Treatment of murine cryptococcosis with liposome-associated amphotericin B
8. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis
9. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study
10. Treatment of systemic fungal infections with liposomal amphotericin B
11. Liposomal Amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation
12. Liposomal and lipid formulations of amphotericin B
13. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations
14. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes
15. Pharmacokinetics of amphotericin B in infants and children
16. Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial
17. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
18. Liposomal amphotericin B
19. Candidiasis in the transplant patient
20. Variables predicting deep fungal infections in bone marrow transplant recipients
21. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients
22. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin
23. Allergic reactions and other rare side-effects of liposomal amphotericin
24. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients - Improvements gained
25. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia
26. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients
27. Long-term follow-up of a randomized trial comparing T-cell-depletion with a combination of methotrexate and cyclosporin in adult leukemic marrow transplant recipients
28. A randomized double-blind study of AmBisome (liposomal amphotericin B) prophylaxis of invasive fungal infections in bone marrow transplant recipients
29. Invasive Candida albicans infections in orthotopic liver graft recipients. Incidence and risk factors
30. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study
31. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infection in liver transplant recipients: Long-term results of a randomized, placebo-controlled trial
32. Lipid formulations of Amphotericin B. Less toxicity but at what economic cost?
33. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis
34. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
35. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
36. Liposomal amphotericin B for empirial therapy in patients with persistent fever and neutropenia
37. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
38. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin b for treatment of invasive aspergillosis
39. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
40. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone marrow transplantation
41. Conventional versus liposomal amphotericin B in immunosuppressed children
42. Liposomal amphotericin B (AmBisome) for treatment of disseminated fungal infections in tw infants of very low birth weight
43. Liposomal amphotericin B. (AmBisome) in neutropenic children with hematological malignancies and systemec fungal infections
44. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer
45. High cure rate of invasive fungal infections in immunocompromised children using AmBisome
46. Opportunistic osteomyelitis in the jaws of children on immunosuppressive chemotherapy
47. Liposomal amphotericin B (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency
48. Candida infection in very low birth-weight infants. Outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome)
49. Treatment of visceral leishmaniasis in children with liposomal amphotericin B
50. Liposomal amphotericin B treatment for neonatal fungal infections
51. Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease
52. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses
53. Pharmacocconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
54. Pharmacoeconomic evaluation of AmBisome in febrile neutropenia